CINECA IRIS Institutional Research Information System

VASILE, ENRICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.427
AS - Asia 1.205
EU - Europa 1.088
SA - Sud America 229
AF - Africa 131
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.084
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.364
SG - Singapore 454
IT - Italia 401
CN - Cina 301
HK - Hong Kong 211
BR - Brasile 190
SE - Svezia 179
GB - Regno Unito 107
DE - Germania 105
VN - Vietnam 97
CI - Costa d'Avorio 79
BG - Bulgaria 64
AT - Austria 53
FR - Francia 40
RU - Federazione Russa 38
CA - Canada 33
IN - India 27
FI - Finlandia 24
PL - Polonia 21
SN - Senegal 18
TR - Turchia 18
JP - Giappone 17
BD - Bangladesh 16
NG - Nigeria 16
MX - Messico 15
AR - Argentina 14
NL - Olanda 14
ES - Italia 12
IQ - Iraq 10
PK - Pakistan 9
ID - Indonesia 6
UZ - Uzbekistan 6
VE - Venezuela 6
SA - Arabia Saudita 5
UA - Ucraina 5
ZA - Sudafrica 5
AE - Emirati Arabi Uniti 4
CO - Colombia 4
CR - Costa Rica 4
CZ - Repubblica Ceca 4
KR - Corea 4
LT - Lituania 4
MA - Marocco 4
PY - Paraguay 4
EC - Ecuador 3
IL - Israele 3
IR - Iran 3
KE - Kenya 3
PA - Panama 3
PE - Perù 3
RO - Romania 3
BY - Bielorussia 2
BZ - Belize 2
CH - Svizzera 2
CL - Cile 2
DK - Danimarca 2
EG - Egitto 2
HN - Honduras 2
MY - Malesia 2
PH - Filippine 2
TN - Tunisia 2
TW - Taiwan 2
UY - Uruguay 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
AU - Australia 1
BE - Belgio 1
DO - Repubblica Dominicana 1
EU - Europa 1
FJ - Figi 1
GD - Grenada 1
GY - Guiana 1
IE - Irlanda 1
JO - Giordania 1
KG - Kirghizistan 1
KH - Cambogia 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
Totale 5.084
Salva come PNG Salva come JPEG
Città #
Ashburn 332
Singapore 220
Hong Kong 210
Chandler 187
Fairfield 183
Dallas 173
Santa Clara 169
Woodbridge 149
Houston 121
Shanghai 88
Abidjan 79
Seattle 79
New York 76
Beijing 75
Ann Arbor 74
Sofia 63
Wilmington 62
Cambridge 60
Milan 59
Boardman 57
Serra 56
London 55
Los Angeles 52
Vienna 48
Munich 47
Florence 40
Princeton 40
Lawrence 36
Pisa 27
Medford 26
Rome 23
Frankfurt am Main 22
Ho Chi Minh City 21
Ottawa 19
Buffalo 18
Dakar 18
San Diego 17
Des Moines 16
Lagos 16
Warsaw 16
Istanbul 14
Ogden 14
Redondo Beach 14
Hanoi 12
Dong Ket 11
Fuzhou 11
São Paulo 11
Turku 11
Düsseldorf 10
Kent 10
Nuremberg 10
Paris 10
Dearborn 9
Helsinki 9
Lancaster 9
Tokyo 9
Belo Horizonte 8
Boulder 8
Bremen 8
Denver 8
Phoenix 8
Mexico City 7
Nanjing 7
Orem 7
Toronto 7
Vicopisano 7
Baghdad 6
Chennai 6
Kunming 6
Poplar 6
Quanzhou 6
Redwood City 6
Stockholm 6
Da Nang 5
Hyderabad 5
Jiaxing 5
Portsmouth 5
Bari 4
Guangzhou 4
Itaquaquecetuba 4
Jakarta 4
Lucca 4
Manaus 4
Manchester 4
Montreal 4
Naples 4
Norwalk 4
Piombino 4
Porto Alegre 4
Rio de Janeiro 4
Tashkent 4
Bacoli 3
Bexley 3
Borgosatollo 3
Brasília 3
Casablanca 3
Chicago 3
Fortaleza 3
Genoa 3
Goiânia 3
Totale 3.523
Salva come PNG Salva come JPEG
Nome #
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA 193
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer 181
Pancreatic resections for metastases: A twenty-year experience from a tertiary care center 181
A patient with MEN1 and end‑stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation 178
Impact of a supportive care service for cancer outpatients: management and reduction of hospitalizations. Preliminary results of an integrated model of care 173
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study 171
HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer 170
Pre-treatment EGFR-T790M subclones in lung adenocarcinoma harboring activating mutation of EGFR: a positive prognostic factor for survival? 166
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment 164
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. 162
First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors 162
Use of zebrafish embryos as avatar of patients with pancreatic cancer: A new xenotransplantation model towards personalized medicine 157
Ampullary adenocarcinomas: The immunohistochemical score of CDX2, CK7 and CK 20 identify pathological subtypes and their prognosis 151
Clinical and economic effect of administration of red blood product transfusions in an outpatient supportive care cancer service 147
Lights and shadows of molecular pathology and immunotherapy in adjuvant setting of patients with pancreatic ductal adenocarcinoma: Tumor volume and microsatellite instability inversely affect early progression free survival 143
First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? 137
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel 137
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer 135
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer 132
Immune checkpoint inhibitors in esophageal cancers: Are we finally finding the right path in the mist? 127
Baseline computed-tomography (CT)-evaluated sarcopenia predicts toxicity from first-line chemotherapy in metastatic gastric cancer (mGC) patients 126
Comment on: 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: An AGEO prospective multicentre cohort' 125
MICROSATELLITE INSTABILITY AND TUMOR VOLUME INVERSELY AFFECT EARLY PROGRESSION FREE SURVIVAL IN ADJUVANT SETTING OF PATIENTS WITH PANCREATIC DUCTAL ADENOCARCINOMA: LIGHTS AND SHADOWS OF MOLECULAR PATHOLOGY AND IMMUNOTHERAPY 123
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 122
Adjuvant radiotherapy in patients with pancreatic adenocarcinoma. Is it still appealing in clinical trials? A meta-analysis and review of the literature 121
Feasibility of BRCA1/2 testing of formalin-fixed and paraffin-embedded pancreatic tumor samples: A consecutive clinical series 107
Robotic Versus Open Pancreatoduodenectomy With Vein Resection and Reconstruction: A Propensity Score-Matched Analysis 105
IDENTIFICATION OF PATHOLOGICAL AMPULLARY ADENOCARCINOMAS SUBTYPES AND THEIR PROGNOSIS USING THE IMMUNOHISTOCHEMICAL SCORE OF CDX2, CK7 AND CK 20 103
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 99
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 98
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: Clinics and pathology are not enough 98
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer 96
Combination chemotherapy in patients with advanced pancreatic cancer with an eastern cooperative oncology group performance status of 2: Lights and shadows of a frail route 90
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 89
FOLFIRINOX Adjuvant Therapy for Pancreatic Cancer 85
ROS1 rearrangements are uncommon in biliary tract cancers 74
Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study 73
Second-line chemotherapy in advanced biliary cancer: The present now will later be past 72
Gastric cancer: Translating novels concepts into clinical practice 70
Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer 67
Evolving Landscape in Liver Transplantation for Hepatocellular Carcinoma: From Stage Migration to Immunotherapy Revolution 53
Stomach preservation in pancreatectomy with celiac axis resection: Prediction and technique via Mayo Clinic classification 18
Totale 5.181
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.914
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.914
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021181 0 0 0 0 0 42 9 15 34 16 19 46
2021/2022371 7 9 7 10 54 84 14 9 12 29 31 105
2022/2023770 69 134 65 36 89 73 4 56 160 7 64 13
2023/2024431 28 30 73 32 44 69 34 7 10 15 43 46
2024/20251.408 9 51 28 85 128 176 80 59 158 181 173 280
2025/20261.091 157 186 204 215 222 107 0 0 0 0 0 0
Totale 5.181